JP2010022372A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2010022372A5 JP2010022372A5 JP2009205660A JP2009205660A JP2010022372A5 JP 2010022372 A5 JP2010022372 A5 JP 2010022372A5 JP 2009205660 A JP2009205660 A JP 2009205660A JP 2009205660 A JP2009205660 A JP 2009205660A JP 2010022372 A5 JP2010022372 A5 JP 2010022372A5
- Authority
- JP
- Japan
- Prior art keywords
- antibody molecule
- seq
- dna
- cdr
- sequence shown
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 101000884305 Homo sapiens B-cell receptor CD22 Proteins 0.000 claims 5
- 206010025323 Lymphomas Diseases 0.000 claims 5
- 239000008194 pharmaceutical composition Substances 0.000 claims 5
- NFGXHKASABOEEW-UHFFFAOYSA-N 1-methylethyl 11-methoxy-3,7,11-trimethyl-2,4-dodecadienoate Chemical compound COC(C)(C)CCCC(C)CC=CC(C)=CC(=O)OC(C)C NFGXHKASABOEEW-UHFFFAOYSA-N 0.000 claims 4
- 208000015914 Non-Hodgkin lymphomas Diseases 0.000 claims 3
- 102000044389 human CD22 Human genes 0.000 claims 3
- LRFVTYWOQMYALW-UHFFFAOYSA-N 9H-xanthine Chemical compound O=C1NC(=O)NC2=C1NC=N2 LRFVTYWOQMYALW-UHFFFAOYSA-N 0.000 claims 2
- 102100038080 B-cell receptor CD22 Human genes 0.000 claims 2
- 239000013599 cloning vector Substances 0.000 claims 2
- 239000013604 expression vector Substances 0.000 claims 2
- 230000001404 mediated effect Effects 0.000 claims 2
- 238000002560 therapeutic procedure Methods 0.000 claims 2
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims 1
- 101710099705 Anti-lipopolysaccharide factor Proteins 0.000 claims 1
- 239000003085 diluting agent Substances 0.000 claims 1
- 201000010099 disease Diseases 0.000 claims 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 238000000034 method Methods 0.000 claims 1
- 239000000203 mixture Substances 0.000 claims 1
- 230000001575 pathological effect Effects 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- 108090000623 proteins and genes Proteins 0.000 claims 1
- 102000004169 proteins and genes Human genes 0.000 claims 1
- 229940075420 xanthine Drugs 0.000 claims 1
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB0210121.0A GB0210121D0 (en) | 2002-05-02 | 2002-05-02 | Biological products |
| GB0210121.0 | 2002-05-02 |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2004501459A Division JP4486494B2 (ja) | 2002-05-02 | 2003-05-02 | 生物学的製剤 |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2013140245A Division JP5920934B2 (ja) | 2002-05-02 | 2013-07-04 | 生物学的製剤 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2010022372A JP2010022372A (ja) | 2010-02-04 |
| JP2010022372A5 true JP2010022372A5 (enExample) | 2010-04-22 |
| JP5377173B2 JP5377173B2 (ja) | 2013-12-25 |
Family
ID=9935990
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2004501459A Expired - Lifetime JP4486494B2 (ja) | 2002-05-02 | 2003-05-02 | 生物学的製剤 |
| JP2009205660A Expired - Lifetime JP5377173B2 (ja) | 2002-05-02 | 2009-09-07 | 生物学的製剤 |
| JP2013140245A Expired - Lifetime JP5920934B2 (ja) | 2002-05-02 | 2013-07-04 | 生物学的製剤 |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2004501459A Expired - Lifetime JP4486494B2 (ja) | 2002-05-02 | 2003-05-02 | 生物学的製剤 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2013140245A Expired - Lifetime JP5920934B2 (ja) | 2002-05-02 | 2013-07-04 | 生物学的製剤 |
Country Status (34)
Families Citing this family (49)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7355012B2 (en) | 2001-09-26 | 2008-04-08 | United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Mutated anti-CD22 antibodies with increased affinity to CD22-expressing leukemia cells |
| US20110045005A1 (en) | 2001-10-19 | 2011-02-24 | Craig Crowley | Compositions and methods for the treatment of tumor of hematopoietic origin |
| EP1476120B1 (en) | 2002-02-21 | 2010-09-29 | Duke University | Treatment methods using anti-cd22 antibodies |
| BR122019027966B8 (pt) * | 2002-05-02 | 2021-07-27 | Wyeth Corp | conjugado monomérico de derivado de caliqueamicina/anti-corpo anti-cd22 e uso dos mesmos |
| GB0210121D0 (en) * | 2002-05-02 | 2002-06-12 | Celltech R&D Ltd | Biological products |
| GB0312481D0 (en) | 2003-05-30 | 2003-07-09 | Celltech R&D Ltd | Antibodies |
| TW200630106A (en) * | 2004-10-08 | 2006-09-01 | Wyeth Corp | Immunotherapy of autoimmune disorders |
| JP2008543839A (ja) | 2005-06-14 | 2008-12-04 | アムジェン インコーポレーテッド | 自己緩衝タンパク質製剤 |
| MY149159A (en) | 2005-11-15 | 2013-07-31 | Hoffmann La Roche | Method for treating joint damage |
| EP2650306A1 (en) | 2006-03-06 | 2013-10-16 | Aeres Biomedical Limited | Humanized Anti-CD22 antibodies and their use in treatment of oncology, transplantation and autoimmune disease |
| AU2007223903B2 (en) * | 2006-03-06 | 2013-09-05 | Medimmune, Llc | Humanized anti-CD22 antibodies and their use in treatment of oncology, transplantation and autoimmune disease |
| PT2032606E (pt) * | 2006-05-30 | 2014-02-05 | Genentech Inc | Anticorpos e imunoconjugados e respetivas utilizações |
| SG177168A1 (en) | 2006-12-01 | 2012-01-30 | Medarex Inc | Human antibodies that bind cd22 and uses thereof |
| WO2009124109A1 (en) * | 2008-04-04 | 2009-10-08 | The Government Of The U.S. A. As Represented By The Secretary Of The Dept. Of Health &Human Services | Human monoclonal antibodies specific for cd22 |
| WO2010075249A2 (en) | 2008-12-22 | 2010-07-01 | Genentech, Inc. | A method for treating rheumatoid arthritis with b-cell antagonists |
| US9238878B2 (en) | 2009-02-17 | 2016-01-19 | Redwood Bioscience, Inc. | Aldehyde-tagged protein-based drug carriers and methods of use |
| JP5996429B2 (ja) | 2009-09-03 | 2016-09-21 | ジェネンテック， インコーポレイテッド | 関節リウマチの治療、診断及びモニターするための方法 |
| EP2663647A4 (en) | 2011-01-14 | 2015-08-19 | Redwood Bioscience Inc | POLYPEPTIDE IMMUNOGLOBULINS WITH ALDEHYDIC MARKING AND THEIR USE METHOD |
| RU2013140975A (ru) | 2011-02-28 | 2015-04-10 | Дженентек, Инк. | Биологические маркеры и способы прогнозирования восприимчивости к антагонистам в-клеток |
| JP2015516984A (ja) * | 2012-04-26 | 2015-06-18 | バイオアトラ、エルエルシー | 抗ｃｄ２２抗体 |
| EP2870176A4 (en) | 2012-07-03 | 2016-09-28 | Univ Washington | ANTIBODIES DIRECTED AGAINST TAU |
| CN104582717B (zh) | 2012-07-19 | 2018-03-13 | 雷德伍德生物科技股份有限公司 | 对cd22有特异性的抗体及其使用方法 |
| CN104822705B (zh) | 2012-10-24 | 2019-07-12 | 美国卫生和人力服务部 | M971嵌合抗原受体 |
| CN103214578B (zh) * | 2013-05-10 | 2014-05-28 | 北京东方百泰生物科技有限公司 | 一种新型的人源化抗cd22抗体 |
| RU2016119491A (ru) | 2013-11-04 | 2017-12-11 | Пфайзер Инк. | Конъюгаты антитела к efna4 с лекарственным средством |
| GB201409558D0 (en) | 2014-05-29 | 2014-07-16 | Ucb Biopharma Sprl | Method |
| TWI734975B (zh) | 2014-06-27 | 2021-08-01 | 美商Ｃ２Ｎ醫療診斷有限責任公司 | 人類化抗-tau抗體 |
| GB201412659D0 (en) | 2014-07-16 | 2014-08-27 | Ucb Biopharma Sprl | Molecules |
| GB201412658D0 (en) | 2014-07-16 | 2014-08-27 | Ucb Biopharma Sprl | Molecules |
| PL3280729T3 (pl) * | 2015-04-08 | 2022-08-22 | Novartis Ag | Terapie cd20, terapie cd22 i terapie skojarzone komórką eksprymującą chimeryczny receptor antygenowy (car) cd19 |
| GB201601075D0 (en) | 2016-01-20 | 2016-03-02 | Ucb Biopharma Sprl | Antibodies molecules |
| GB201601073D0 (en) | 2016-01-20 | 2016-03-02 | Ucb Biopharma Sprl | Antibodies |
| GB201601077D0 (en) * | 2016-01-20 | 2016-03-02 | Ucb Biopharma Sprl | Antibody molecule |
| WO2017083306A1 (en) | 2015-11-09 | 2017-05-18 | R.P. Scherer Technologies, Llc | Anti-cd22 antibody-maytansine conjugates and methods of use thereof |
| GB201521393D0 (en) | 2015-12-03 | 2016-01-20 | Ucb Biopharma Sprl | Antibodies |
| GB201521383D0 (en) | 2015-12-03 | 2016-01-20 | Ucb Biopharma Sprl And Ucb Celltech | Method |
| GB201521391D0 (en) | 2015-12-03 | 2016-01-20 | Ucb Biopharma Sprl | Antibodies |
| GB201521382D0 (en) | 2015-12-03 | 2016-01-20 | Ucb Biopharma Sprl | Antibodies |
| GB201521389D0 (en) | 2015-12-03 | 2016-01-20 | Ucb Biopharma Sprl | Method |
| CA3019398A1 (en) | 2016-04-26 | 2017-11-02 | R.P. Scherer Technologies, Llc | Antibody conjugates and methods of making and using the same |
| GB201610512D0 (en) | 2016-06-16 | 2016-08-03 | Autolus Ltd | Chimeric antigen receptor |
| ES3064802T3 (en) | 2016-10-21 | 2026-04-29 | Amgen Inc | Pharmaceutical formulations and methods of making the same |
| CN112888709B (zh) | 2018-03-30 | 2024-10-29 | 优瑞科生物技术公司 | 标靶cd22的构建体和其用途 |
| EP4130040A4 (en) * | 2020-04-02 | 2024-05-01 | Nanjing Iaso Biotechnology Co., Ltd. | Fully human anti-human cd22 chimeric antigen receptor and application thereof |
| WO2022042494A1 (zh) * | 2020-08-27 | 2022-03-03 | 深圳市菲鹏生物治疗股份有限公司 | Cd22抗体及其应用 |
| WO2022262783A1 (zh) * | 2021-06-16 | 2022-12-22 | 西安宇繁生物科技有限责任公司 | 抗cd22的全人源抗体或其抗原结合片段及其制备方法和应用 |
| US20250129180A1 (en) * | 2021-08-27 | 2025-04-24 | Peptron, Inc. | Novel anti-muc1 antibody and use thereof |
| CN119751680A (zh) * | 2021-12-06 | 2025-04-04 | 重庆精准生物技术有限公司 | 靶向cd22的抗原结合片段和单链抗体及其应用 |
| WO2024102693A2 (en) | 2022-11-07 | 2024-05-16 | Xencor, Inc. | Il-18-fc fusion proteins |
Family Cites Families (38)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3957362A (en) * | 1972-10-02 | 1976-05-18 | Corneal Sciences, Inc. | Hydrogels and articles made therefrom |
| GB8607679D0 (en) | 1986-03-27 | 1986-04-30 | Winter G P | Recombinant dna product |
| US5225539A (en) * | 1986-03-27 | 1993-07-06 | Medical Research Council | Recombinant altered antibodies and methods of making altered antibodies |
| IL162181A (en) | 1988-12-28 | 2006-04-10 | Pdl Biopharma Inc | A method of producing humanized immunoglubulin, and polynucleotides encoding the same |
| US5530101A (en) * | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
| US5134075A (en) * | 1989-02-17 | 1992-07-28 | Oncogen Limited Partnership | Monoclonal antibody to novel antigen associated with human tumors |
| GB8928874D0 (en) * | 1989-12-21 | 1990-02-28 | Celltech Ltd | Humanised antibodies |
| DE69133528T2 (de) * | 1990-06-27 | 2006-09-07 | Princeton University | Proteinkomplex p53/p90 |
| AU658396B2 (en) * | 1991-03-06 | 1995-04-13 | Merck Patent Gesellschaft Mit Beschrankter Haftung | Humanized and chimeric monoclonal antibodies |
| US5714350A (en) * | 1992-03-09 | 1998-02-03 | Protein Design Labs, Inc. | Increasing antibody affinity by altering glycosylation in the immunoglobulin variable region |
| US5686072A (en) | 1992-06-17 | 1997-11-11 | Board Of Regents, The University Of Texas | Epitope-specific monoclonal antibodies and immunotoxins and uses thereof |
| US5714340A (en) * | 1992-12-22 | 1998-02-03 | Johnson & Johnson Clinical Diagnostics, Inc. | Immunoassay elements having a receptor zone |
| US6180377B1 (en) * | 1993-06-16 | 2001-01-30 | Celltech Therapeutics Limited | Humanized antibodies |
| US5436265A (en) * | 1993-11-12 | 1995-07-25 | Merck Frosst Canada, Inc. | 1-aroyl-3-indolyl alkanoic acids and derivatives thereof useful as anti-inflammatory agents |
| US5474995A (en) | 1993-06-24 | 1995-12-12 | Merck Frosst Canada, Inc. | Phenyl heterocycles as cox-2 inhibitors |
| DE69535133T2 (de) * | 1994-01-25 | 2008-08-21 | Elan Pharmaceuticals, Inc., San Francisco | Humanisierte antikörper gegen das leukozytenadhäsionsmolekül vla-4 |
| DE69521002T3 (de) | 1994-08-12 | 2010-02-25 | The University Of Utah Research Foundation, Salt Lake City | Mutationen des mit 17q verbundenen Ovarial- und Brustkrebs Empfindlichkeitsgens |
| AU3272695A (en) * | 1994-08-12 | 1996-03-07 | Immunomedics Inc. | Immunoconjugates and humanized antibodies specific for b-cell lymphoma and leukemia cells |
| US5714586A (en) * | 1995-06-07 | 1998-02-03 | American Cyanamid Company | Methods for the preparation of monomeric calicheamicin derivative/carrier conjugates |
| US5712374A (en) * | 1995-06-07 | 1998-01-27 | American Cyanamid Company | Method for the preparation of substantiallly monomeric calicheamicin derivative/carrier conjugates |
| US7147851B1 (en) * | 1996-08-15 | 2006-12-12 | Millennium Pharmaceuticals, Inc. | Humanized immunoglobulin reactive with α4β7 integrin |
| US20020141990A1 (en) * | 1996-11-01 | 2002-10-03 | Smithkline Beecham Corporation | Anti-RSV human monoclonal antibodies |
| JP2001510329A (ja) * | 1996-11-01 | 2001-07-31 | スミスクライン・ビーチャム・コーポレイション | ヒトモノクローナル抗体 |
| US5980898A (en) | 1996-11-14 | 1999-11-09 | The United States Of America As Represented By The U.S. Army Medical Research & Material Command | Adjuvant for transcutaneous immunization |
| WO1998041641A1 (en) | 1997-03-20 | 1998-09-24 | The Government Of The United States As Represented By The Secretary Of The Department Of Health And Human Services | Recombinant antibodies and immunoconjugates targeted to cd-22 bearing cells and tumors |
| US6183744B1 (en) * | 1997-03-24 | 2001-02-06 | Immunomedics, Inc. | Immunotherapy of B-cell malignancies using anti-CD22 antibodies |
| ATE230277T1 (de) | 1997-06-13 | 2003-01-15 | Genentech Inc | Stabilisierte antikörperformulierung |
| AT408613B (de) * | 1998-06-17 | 2002-01-25 | Immuno Ag | Pharmazeutisches faktor vii-präparat |
| KR100345463B1 (ko) * | 1998-11-19 | 2003-01-08 | 주)녹십자 | B형간염바이러스의표면항원프리-s1에대한인간화항체및이의제조방법 |
| DE60042785D1 (de) * | 1999-06-09 | 2009-10-01 | Immunomedics Inc | Immuntherapie von autoimmunerkrankungen durch die verwendung von b-zell spezifischen antikörpern |
| EP1232392B2 (de) * | 1999-10-12 | 2014-04-02 | Oxoid (Ely) Limited | Verbessertes verfahren zum nachweis von säure-resistenten bakterien der gattung helicobacter im stuhl |
| US20010046496A1 (en) * | 2000-04-14 | 2001-11-29 | Brettman Lee R. | Method of administering an antibody |
| GB0013810D0 (en) * | 2000-06-06 | 2000-07-26 | Celltech Chiroscience Ltd | Biological products |
| JP2004502742A (ja) * | 2000-07-12 | 2004-01-29 | アイデック ファーマスーティカルズ コーポレイション | Ｂ細胞を消滅させる抗体及び免疫調節抗体を併用するｂ細胞悪性疾患の治療関連出願 |
| CN1205479C (zh) * | 2000-10-31 | 2005-06-08 | 杨梦甦 | 免疫学诊断蛋白芯片制备方法 |
| GB0210121D0 (en) * | 2002-05-02 | 2002-06-12 | Celltech R&D Ltd | Biological products |
| BR122019027966B8 (pt) * | 2002-05-02 | 2021-07-27 | Wyeth Corp | conjugado monomérico de derivado de caliqueamicina/anti-corpo anti-cd22 e uso dos mesmos |
| EP2650306A1 (en) * | 2006-03-06 | 2013-10-16 | Aeres Biomedical Limited | Humanized Anti-CD22 antibodies and their use in treatment of oncology, transplantation and autoimmune disease |
-
2002
- 2002-05-02 GB GBGB0210121.0A patent/GB0210121D0/en not_active Ceased
-
2003
- 2003-05-02 TW TW092112182A patent/TWI324161B/zh not_active IP Right Cessation
- 2003-05-02 MX MXPA04010787A patent/MXPA04010787A/es active IP Right Grant
- 2003-05-02 PL PL373277A patent/PL218433B1/pl unknown
- 2003-05-02 DK DK03718974.3T patent/DK1504035T6/en active
- 2003-05-02 CA CA2484420A patent/CA2484420C/en not_active Expired - Lifetime
- 2003-05-02 SI SI200331804T patent/SI1504035T1/sl unknown
- 2003-05-02 SG SG200608406-5A patent/SG161744A1/en unknown
- 2003-05-02 KR KR1020127025129A patent/KR101386376B1/ko not_active Expired - Lifetime
- 2003-05-02 KR KR1020107027192A patent/KR101238970B1/ko not_active Expired - Lifetime
- 2003-05-02 AT AT03718974T patent/ATE462729T3/de unknown
- 2003-05-02 DE DE60331910T patent/DE60331910D1/de not_active Expired - Lifetime
- 2003-05-02 KR KR1020047017615A patent/KR101156796B1/ko not_active Expired - Lifetime
- 2003-05-02 NZ NZ536757A patent/NZ536757A/en not_active IP Right Cessation
- 2003-05-02 CN CN201310021287.1A patent/CN103172742B/zh not_active Expired - Lifetime
- 2003-05-02 RU RU2004135103/13A patent/RU2342401C2/ru active
- 2003-05-02 US US10/428,408 patent/US7355011B2/en not_active Expired - Lifetime
- 2003-05-02 JP JP2004501459A patent/JP4486494B2/ja not_active Expired - Lifetime
- 2003-05-02 EP EP03718974.3A patent/EP1504035B9/en not_active Expired - Lifetime
- 2003-05-02 CN CNB038150433A patent/CN100384878C/zh not_active Expired - Lifetime
- 2003-05-02 PT PT03718974T patent/PT1504035E/pt unknown
- 2003-05-02 UA UA20041209866A patent/UA92580C2/ru unknown
- 2003-05-02 CN CN2007100852904A patent/CN101134779B/zh not_active Expired - Lifetime
- 2003-05-02 WO PCT/GB2003/001934 patent/WO2003093320A2/en not_active Ceased
- 2003-05-02 ES ES03718974.3T patent/ES2341708T7/es active Active
- 2003-05-02 AU AU2003223007A patent/AU2003223007C1/en active Active
-
2004
- 2004-10-28 IL IL164923A patent/IL164923A/en active IP Right Grant
- 2004-11-02 ZA ZA2004/08851A patent/ZA200408851B/en unknown
- 2004-11-02 NO NO20044742A patent/NO336201B3/no not_active IP Right Cessation
- 2004-11-30 CO CO04120665A patent/CO5631451A2/es active IP Right Grant
- 2004-12-02 EC EC2004005470A patent/ECSP045470A/es unknown
-
2006
- 2006-09-11 US US11/519,585 patent/US20070059307A1/en not_active Abandoned
-
2008
- 2008-09-23 US US12/235,724 patent/US7919606B2/en not_active Expired - Lifetime
-
2009
- 2009-09-07 JP JP2009205660A patent/JP5377173B2/ja not_active Expired - Lifetime
-
2010
- 2010-06-03 CY CY20101100492T patent/CY1110134T1/el unknown
-
2011
- 2011-03-16 US US13/049,087 patent/US8895714B2/en not_active Expired - Lifetime
-
2012
- 2012-07-13 US US13/548,542 patent/US20120302739A1/en not_active Abandoned
-
2013
- 2013-07-04 JP JP2013140245A patent/JP5920934B2/ja not_active Expired - Lifetime
-
2016
- 2016-03-14 US US15/069,078 patent/US20160326247A1/en not_active Abandoned
-
2017
- 2017-01-27 US US15/417,973 patent/US20170145114A1/en not_active Abandoned
- 2017-12-20 CY CY2017046C patent/CY2017046I1/el unknown
- 2017-12-21 NO NO2017068C patent/NO2017068I1/no unknown
- 2017-12-21 LU LU00058C patent/LUC00058I2/en unknown
- 2017-12-21 CY CY2017045C patent/CY2017045I2/el unknown
- 2017-12-21 LT LTPA2017044C patent/LTC1504035I2/lt unknown
- 2017-12-21 BE BE2017C068C patent/BE2017C068I2/nl unknown
- 2017-12-21 NO NO2017069C patent/NO2017069I1/no unknown
- 2017-12-21 FR FR17C1062C patent/FR17C1062I2/fr active Active
- 2017-12-21 LT LTPA2017043C patent/LTPA2017043I1/lt unknown
- 2017-12-21 NL NL300920C patent/NL300920I2/nl unknown
- 2017-12-21 LU LU00057C patent/LUC00057I2/en unknown
- 2017-12-22 HU HUS1700056C patent/HUS1700056I1/hu unknown
- 2017-12-22 HU HUS1700055C patent/HUS1700055I1/hu unknown
-
2021
- 2021-01-19 US US17/151,911 patent/US20210371547A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2016512551A5 (enExample) | ||
| NZ596136A (en) | Anti-cd100 antibodies and methods for using the same | |
| TWI769537B (zh) | 標靶ｂｃｍａ的抗體、雙專一性抗體及其用途 | |
| JP2006506955A5 (enExample) | ||
| HRP20190932T1 (hr) | Molekule protutijela koje se vežu na il-17a i il-17f | |
| JP2022516881A5 (enExample) | ||
| JP2016511750A5 (enExample) | ||
| JP2017505604A5 (enExample) | ||
| JP2014534242A5 (enExample) | ||
| JP2015504306A5 (enExample) | ||
| JP2015509948A5 (enExample) | ||
| JP2021524267A5 (enExample) | ||
| AR080243A1 (es) | Composiciones y metodos para el diagnostico y tratamiento de tumores | |
| NZ603045A (en) | Tnf-alpha binding proteins | |
| NZ596712A (en) | Anti cxcr4 antibodies for the treatment of hiv | |
| JP2012530496A5 (enExample) | ||
| HRP20191983T1 (hr) | Konstrukti protutijela za cdh19 i cd3 | |
| AR122761A1 (es) | Moléculas de unión a antígeno biespecíficas anti-cd3 / anti-cd28 | |
| RU2008149918A (ru) | Антитела к nkg2a и их применения | |
| JP7161400B2 (ja) | Ｃｄ２２に結合する抗体分子 | |
| JP2013524773A5 (enExample) | ||
| JP2010524435A5 (enExample) | ||
| JP2016536020A5 (enExample) | ||
| RU2010133892A (ru) | Гуманизированные моноклональные антитела против человеческого nkg2a | |
| HRP20191697T1 (hr) | Vezujuće molekule za bcma i cd3 |